NeuroSigma.png
NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
March 01, 2023 11:00 ET | NeuroSigma, Inc.
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced a new option for patients and caregivers seeking a telehealth evaluation for the Monarch eTNS System®. NeuroSigma is a Los...
New Logo July 12, 2022.png
Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
January 12, 2023 08:30 ET | Odyssey Health, Inc
Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
New Logo July 12, 2022.png
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
December 19, 2022 08:30 ET | Odyssey Health, Inc
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today...
New Logo July 12, 2022.png
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
November 23, 2022 08:30 ET | Odyssey Health, Inc
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
New Logo July 12, 2022.png
Odyssey Health, Inc. Schedules Annual Meeting of Stockholders
November 15, 2022 08:00 ET | Odyssey Health, Inc
Las Vegas, Nevada, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on...
New Logo July 12, 2022.png
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
November 03, 2022 08:30 ET | Odyssey Health, Inc
Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on...
New Logo July 12, 2022.png
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
November 01, 2022 08:30 ET | Odyssey Health, Inc
Las Vegas, Nevada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), announces that it has filed for United...
AMR Logo.png
Global Speech Therapy Market is Expected to Reach USD 17 Billion by 2031: Says AMR
October 31, 2022 05:08 ET | Allied Market Research
Portland, OR, Oct. 31, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Speech Therapy Market was estimated at $9.9 billion in 2021 and is...
NeuroSigma.png
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
October 17, 2022 09:00 ET | NeuroSigma, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...
New Logo July 12, 2022.png
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
October 11, 2022 08:30 ET | Odyssey Health, Inc
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...